Axisresearch
List of Categories
- Aerospace & Defense
- Agriculture
- Animal Nutrition & Wellness
- Automation
- Automotive
- Chemical & Materials
- Consumer Goods and Services
- Electronics
- Energy & Mining
- Financial Services & Investment Intelligence
- Food & Beverage
- Healthcare
- Heavy Industry
- Home & Property Improvement
- Information & Communications Technology
- Investment Opportunities
- Manufacturing
- NEO
- Others
- Packaging
- Retail
- Technology & Media
- Transportation & Logistics
Sorted by Name
Publishers
Countries
Asia-Pacific Diabetes Care Drugs Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 90 pages | Published: 12-06-2019 |
- Healthcare
- Mordor Intelligence
- 90 pages
- Published: 12-06-2019
Market Overview
The Asia-Pacific market for diabetes drugs is estimated to value USD 23.8 billion in 2019, and the market is expected to grow at the CAGR of 4.82%, during the forecast period.
Over the past few decades, Asian countries have witnessed a rapid increase in diabetes patients, especially those with type 2 diabetes. Developing countries have more than 70% of the global diabetes population.
The Asian population gets diabetes at a younger age in comparison to the Western population. The reason for this early diabetes development is the sudden change in lifestyle, due to rapid economic growth.
Asia contributes approximately 60% of the total diabetes patients in the world. The most obvious reason for this is that two of the most populated countries in the world are in Asia.
Scope of the Report
The Asia-Pacific diabetes drugs report covered by category (insulin, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs), by segment (basal or long-acting, bolus or fast-acting, traditional human insulin drugs, insulin biosimilars, GLP-1 receptor agonists, alpha-glucosidase inhibitors, DPP-4 inhibitors, and SGLT-2 inhibitors), and by countries.
Key Market Trends
Oral Anti-Diabetes Drugs Take 67% of the Asia-Pacific Diabetes Drugs Market.
The use of oral anti-diabetes drugs is rising, due to the fact that new generation oral drugs, such as DPP-4 and SGLT-2, reduce the rate of CV risk in diabetes patients.
SGLT-2 and GLP-1 are linked to lowering the mortality rate more effectively than DPP-4 inhibitors.
Meglitinide and sulfonylureas are oral hypoglycemic drugs that directly arouse the discharge of insulin from pancreatic beta cells. They hold a significant market share, of 14.27% and 9.62%, respectively, in the Asia-Pacific anti-diabetics drugs market.
China and Japan Occupy more than a 50% Share in the Asia-Pacific Diabetes Drugs Market.
In the Asia-Pacific region, China and Japan have recognized as potential developing markets, due to the growing diabetic population in this region.
Japan is a mature market, with some associated challenges, like slow economic growth, the aging population, and increased competition. One particular challenge in this region is the growing preference for oral anti-diabetics among type-2 diabetic patients, thereby, leading to a negative insulin volume development.
China has the highest market share and is expected to grow with a steady CAGR of 4%. It also contributes 15% to the global diabetes drugs market.
The country is witnessing a significant increase in the number of generic drug manufacturers. Furthermore, the leading global players in the market studied are facing intense competition from the regional players.
Competitive Landscape
The Asia-Pacific diabetes care drugs market is highly fragmented, with a few major manufacturers gaining presence in major countries of the Asia-Pacific market, while the remaining market comprises other local or region-specific manufacturers.
Mergers and acquisitions that happened between players in the recent past helped companies strengthen their market presence, as well as driving innovations, helping the diabetes drugs market to increase in the Asia-Pacific region. For instance, Biocon has launched its insulin glargine biosimilar, in Japan and Malaysia, partnering with local manufacturers for further commercialization.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Drug
5.1.1 Oral Anti-diabetic Drugs
5.1.1.1 Biguanides (Value and Volume 2012-2024)
5.1.1.1.1 Metformin
5.1.1.2 Alpha – Glucosidase Inhibitors (Value and Volume 2012-2024)
5.1.1.2.1 Alpha – Glucosidase Inhibitors
5.1.1.3 Dopamine -D2 Receptor Agonist (Value and Volume 2012-2024)
5.1.1.3.1 Bromocriptin (Cycloset)
5.1.1.4 Sodium-glucose Cotransport -2 (SGLT-2) Inhibitor (Value and Volume 2012-2024)
5.1.1.4.1 Invokana (Canagliflozin)
5.1.1.4.2 Jardiance (Empagliflozin)
5.1.1.4.3 Farxiga/Forxiga (Dapagliflozin)
5.1.1.4.4 Suglat (Ipragliflozin)
5.1.1.5 Dipeptidyl Peptidase – 4 (DPP-4) Inhibitors (Value and Volume 2012-2024)
5.1.1.5.1 Januvia (Sitagliptin)
5.1.1.5.2 Onglyza (Saxagliptin)
5.1.1.5.3 Tradjenta (Linagliptin)
5.1.1.5.4 Vipidia/Nesina (Alogliptin)
5.1.1.5.5 Galvus (Vildagliptin)
5.1.1.6 Sulfonylureas (Value and Volume 2012-2024)
5.1.1.6.1 Sulfonylureas
5.1.1.7 Meglitinides (Value and Volume 2012-2024)
5.1.1.7.1 Meglitinides
5.1.2 Insulin
5.1.2.1 Basal or Long-acting Insulins
5.1.2.1.1 Lantus (Insulin Glargine)
5.1.2.1.2 Levemir (Insulin Detemir)
5.1.2.1.3 Toujeo (Insulin Glargine)
5.1.2.1.4 Tresiba (Insulin Degludec)
5.1.2.1.5 Basaglar (Insulin Glargine)
5.1.2.2 Bolus or Fast-acting Insulins
5.1.2.2.1 NovoRapid/Novolog (Insulin Aspart)
5.1.2.2.2 Humalog (Insulin Lispro)
5.1.2.2.3 Apidra (Insulin Glulisine)
5.1.2.3 Traditional Human Insulins
5.1.2.3.1 Novolin/Actrapid/Insulatard
5.1.2.3.2 Humilin
5.1.2.3.3 Insuman
5.1.2.4 Biosimilar Insulins
5.1.2.4.1 Insulin Glargine Biosimilars
5.1.2.4.2 Human Insulin Biosimilars
5.1.3 Non-insulin Injectable Drugs
5.1.3.1 GLP-1 Receptor Agonists
5.1.3.1.1 Victoza (Liraglutide)
5.1.3.1.2 Byetta (Exenatide)
5.1.3.1.3 Bydureon (Exenatide)
5.1.3.1.4 Trulicity (Dulaglutide)
5.1.3.1.5 Lyxumia (Lixisenatide)
5.1.3.2 Amylin Analogue
5.1.3.2.1 Symlin (Pramlintide)
5.1.4 Combination Drugs
5.1.4.1 Insulin Combinations
5.1.4.1.1 NovoMix (Biphasic Insulin Aspart)
5.1.4.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
5.1.4.1.3 Xultophy (Insulin Degludec and Liraglutide)
5.1.4.2 Oral Combination
5.1.4.2.1 Janumet (Sitagliptin and Metformin HCl)
5.2 Geography
5.2.1 Asia-Pacific
5.2.1.1 Australia (Value and Volume 2012-2024)
5.2.1.1.1 Oral Anti-diabetic Drugs
5.2.1.1.2 Insulin
5.2.1.1.3 Non-Insulin Injectable Drugs
5.2.1.1.4 Combination Drugs
5.2.1.1.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
5.2.1.2 China (Value and Volume 2012-2024)
5.2.1.2.1 Oral Anti-diabetic Drugs
5.2.1.2.2 Insulin
5.2.1.2.3 Non-Insulin Injectable Drugs
5.2.1.2.4 Combination Drugs
5.2.1.2.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
5.2.1.3 India (Value and Volume 2012-2024)
5.2.1.3.1 Oral Anti-diabetic Drugs
5.2.1.3.2 Insulin
5.2.1.3.3 Non-Insulin Injectable Drugs
5.2.1.3.4 Combination Drugs
5.2.1.3.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
5.2.1.4 Indonesia (Value and Volume 2012-2024)
5.2.1.4.1 Oral Anti-diabetic Drugs
5.2.1.4.2 Insulin
5.2.1.4.3 Non-Insulin Injectable Drugs
5.2.1.4.4 Combination Drugs
5.2.1.4.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
5.2.1.5 Japan (Value and Volume 2012-2024)
5.2.1.5.1 Oral Anti-diabetic Drugs
5.2.1.5.2 Insulin
5.2.1.5.3 Non-Insulin Injectable Drugs
5.2.1.5.4 Combination Drugs
5.2.1.5.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
5.2.1.6 Malaysia (Value and Volume 2012-2024)
5.2.1.6.1 Oral Anti-diabetic Drugs
5.2.1.6.2 Insulin
5.2.1.6.3 Non-Insulin Injectable Drugs
5.2.1.6.4 Combination Drugs
5.2.1.6.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
5.2.1.7 Philippines (Value and Volume 2012-2024)
5.2.1.7.1 Oral Anti-diabetic Drugs
5.2.1.7.2 Insulin
5.2.1.7.3 Non-Insulin Injectable Drugs
5.2.1.7.4 Combination Drugs
5.2.1.7.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
5.2.1.8 South Korea (Value and Volume 2012-2024)
5.2.1.8.1 Oral Anti-diabetic Drugs
5.2.1.8.2 Insulin
5.2.1.8.3 Non-Insulin Injectable Drugs
5.2.1.8.4 Combination Drugs
5.2.1.8.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
5.2.1.9 Thailand (Value and Volume 2012-2024)
5.2.1.9.1 Oral Anti-diabetic Drugs
5.2.1.9.2 Insulin
5.2.1.9.3 Non-Insulin Injectable Drugs
5.2.1.9.4 Combination Drugs
5.2.1.9.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
5.2.1.10 Vietnam (Value and Volume 2012-2024)
5.2.1.10.1 Oral Anti-diabetic Drugs
5.2.1.10.2 Insulin
5.2.1.10.3 Non-Insulin Injectable Drugs
5.2.1.10.4 Combination Drugs
5.2.1.10.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
5.2.1.11 Rest of Asia Pacific (Value and Volume 2012-2024)
5.2.1.11.1 Oral Anti-diabetic Drugs
5.2.1.11.2 Insulin
5.2.1.11.3 Non-Insulin Injectable Drugs
5.2.1.11.4 Combination Drugs
5.2.1.11.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
6 MARKET INDICATORS
6.1 Type-1 Diabetes Population (2012-2024)
6.2 Type-2 Diabetes Population (2012-2024)
7 COMPETITIVE LANDSCAPE
7.1 Company Profiles
7.1.1 Takeda
7.1.2 Pfizer
7.1.3 Eli Lilly
7.1.4 Janssen Pharmaceuticals
7.1.5 Astellas
7.1.6 Boehringer Ingelheim
7.1.7 Merck And Co.
7.1.8 AstraZeneca
7.1.9 Bristol Myers Squibb
7.1.10 Novartis
7.1.11 Sanofi
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Drug
Oral Anti-diabetic Drugs
Biguanides (Value and Volume 2012-2024)
Metformin
Alpha – Glucosidase Inhibitors (Value and Volume 2012-2024)
Alpha – Glucosidase Inhibitors
Dopamine -D2 Receptor Agonist (Value and Volume 2012-2024)
Bromocriptin (Cycloset)
Sodium-glucose Cotransport -2 (SGLT-2) Inhibitor (Value and Volume 2012-2024)
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
Dipeptidyl Peptidase – 4 (DPP-4) Inhibitors (Value and Volume 2012-2024)
Januvia (Sitagliptin)
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina (Alogliptin)
Galvus (Vildagliptin)
Sulfonylureas (Value and Volume 2012-2024)
Sulfonylureas
Meglitinides (Value and Volume 2012-2024)
Meglitinides
Insulin
Basal or Long-acting Insulins
Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Basaglar (Insulin Glargine)
Bolus or Fast-acting Insulins
NovoRapid/Novolog (Insulin Aspart)
Humalog (Insulin Lispro)
Apidra (Insulin Glulisine)
Traditional Human Insulins
Novolin/Actrapid/Insulatard
Humilin
Insuman
Biosimilar Insulins
Insulin Glargine Biosimilars
Human Insulin Biosimilars
Non-insulin Injectable Drugs
GLP-1 Receptor Agonists
Victoza (Liraglutide)
Byetta (Exenatide)
Bydureon (Exenatide)
Trulicity (Dulaglutide)
Lyxumia (Lixisenatide)
Amylin Analogue
Symlin (Pramlintide)
Combination Drugs
Insulin Combinations
NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
Oral Combination
Janumet (Sitagliptin and Metformin HCl)
Geography
Asia-Pacific
Australia (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
China (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
India (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
Indonesia (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
Japan (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
Malaysia (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
Philippines (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
South Korea (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
Thailand (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
Vietnam (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
Rest of Asia Pacific (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
Asia-Pacific Glucagon like Peptide – 1 (GLP – 1) Agonists Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 100 pages | Published: 13-06-2019 |
- Healthcare
- Mordor Intelligence
- 100 pages
- Published: 13-06-2019
Market Overview
The GLP-1 drugs are also known as “incretin mimetics,” a hormone that stimulates insulin secretion in response to meals.
GLP-1s are considered an adjunct to diet and exercise, to improve glycemic control in adults with type-2 diabetes mellitus.
Patients with type-2 diabetes have diminished insulin release in response to meals, and it is speculated that they may have defects in the release or action of their incretin hormones.
Diabetes prevalence has increased rapidly in recent decades. It is estimated that in 2007, more than 100 million Asians were living with diabetes. Concurrently with the rise in the diabetic population, obesity is also rising sharply because of economic development, increasing sedentary lifestyles, and nutrition transition.
Asia contributes approximately 60% of the total diabetes patients in the world. The most obvious reason for this is that two of the most populated countries in the world are in Asia, i.e., China and Japan.
Scope of the Report
The Asia-Pacific region suffers from a high burden of diabetes, and its adverse health and economic consequences.
The disease is not only viewed as a serious threat, just from a public health perspective, but also from a development perspective.
With risk factors, such as obesity increasing, and progressively aging populations, the diabetes epidemic is growing, especially in the low- and middle-income countries of the region.
It is one of the most common chronic diseases in China and India. The market is segmented by drug (Exenatide, Liraglutide, Dulaglutide, Lixisenatide), by brand (Byetta, Bydureon, Victoza, Trulicity, Lyxumia), and by geography.
Key Market Trends
Ever Increasing Prevalence of Diabetes
China tops the global list of countries for the total number of people with diabetes, followed by India. The number of people with diabetes in Japan has also increased significantly.
According to the IDF in 2013, it is estimated that Japan occupied the 10th position in the IDF list, with 7.2 million people with diabetes.
WHO projects that diabetes is likely to be the seventh leading cause of death by 2030. Almost half of all deaths attributable to high blood glucose occur before the age of 70 years.
The growing prevalence of diabetes is the primary driver for the Asia-Pacific diabetes care market. Additionally, rising awareness regarding diabetes care, the ever-increasing prevalence of obesity, and technological advancements are further driving the market.
Japan is Dominating the GLP-1 Market in the Asia-Pacific Region
Japan holds the highest share in the Asia-Pacific GLP-1 agonist market, followed by China. GLP-1 receptor agonists have effective glucose-lowering efficacies and remarkable weight-loss effects, and are beneficial for diabetes treatment, especially for patients with overweight/obesity.
In Asia-Pacific, the revenue generated by the GLP-1 market was USD 384.04 million in 2017, and the market is expected to grow steadily during the forecast period, at a considerable rate of 15.93%. The growth of the market can be attributed to the fact that the type-2 diabetic population is on the rise and is expected to see further increase in the future, due to the lifestyle choices of individuals.
By brand, Victoza occupies the significant market share, at 62.07%, and it is expected to witness a growth rate of 11.49% during the forecast period. Trulicity held 26.24%, as of 2017.
Trulicity has a growth rate of 25.48% and is expected to reach almost the same overall market value as of Victoza, by 2024.
Competitive Landscape
The Asia-Pacific GLP-1 market is consolidated, with four major manufacturers holding a presence in the region.
Currently, no generic versions of the GLP-1s are available in the market, since the drugs are patent protected. However, Sajjala Bio, Hyderabad, India, recently announced developments in a liraglutide biosimilar, and the company is aiming to launch the product by the end of 2019.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET INDICATORS
5.1 Type-1 Diabetes Population (2012-2024)
5.2 Type-2 Diabetes Population (2012-2024)
6 MARKET SEGMENTATION
6.1 By Drug
6.1.1 Exenatide
6.1.1.1 Byetta (Value and Volume, 2012-2024)
6.1.1.2 Bydureon (Value and Volume, 2012-2024)
6.1.2 Liraglutide
6.1.2.1 Victoza (Value and Volume, 2012-2024)
6.1.3 Lixisenatide
6.1.3.1 Lyxumia (Value and Volume, 2012-2024)
6.1.4 Dulaglutide
6.1.4.1 Trulicity (Value and Volume, 2012-2024)
6.2 Geography
6.2.1 Asia-Pacific
6.2.1.1 Japan (Value and Volume, 2012-2024)
6.2.1.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
6.2.1.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
6.2.1.2 China (Value and Volume, 2012-2024)
6.2.1.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
6.2.1.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
6.2.1.3 Australia (Value and Volume, 2012-2024)
6.2.1.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
6.2.1.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
6.2.1.4 India (Value and Volume, 2012-2024)
6.2.1.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
6.2.1.4.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
6.2.1.5 South Korea (Value and Volume, 2012-2024)
6.2.1.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
6.2.1.5.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
6.2.1.6 Malaysia (Value and Volume, 2012-2024)
6.2.1.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
6.2.1.6.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
6.2.1.7 Indonesia (Value and Volume, 2012-2024)
6.2.1.7.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
6.2.1.7.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
6.2.1.8 Thailand (Value and Volume, 2012-2024)
6.2.1.8.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
6.2.1.8.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
6.2.1.9 Philippines (Value and Volume, 2012-2024)
6.2.1.9.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
6.2.1.9.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
6.2.1.10 Rest of Asia-Pacific (Value and Volume, 2012-2024)
6.2.1.10.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
6.2.1.10.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
7 COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Novo Nordisk
7.1.2 Sanofi Aventis
7.1.3 Eli Lilly
7.1.4 Astra Zeneca
7.2 MARKET SHARE ANALYSIS
7.2.1 Novo Nordisk
7.2.2 Sanofi Aventis
7.2.3 Eli Lilly
7.2.4 Astra Zeneca
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Drug
Exenatide
Byetta (Value and Volume, 2012-2024)
Bydureon (Value and Volume, 2012-2024)
Liraglutide
Victoza (Value and Volume, 2012-2024)
Lixisenatide
Lyxumia (Value and Volume, 2012-2024)
Dulaglutide
Trulicity (Value and Volume, 2012-2024)
Geography
Asia-Pacific
Japan (Value and Volume, 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
China (Value and Volume, 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Australia (Value and Volume, 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
India (Value and Volume, 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
South Korea (Value and Volume, 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Malaysia (Value and Volume, 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Indonesia (Value and Volume, 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Thailand (Value and Volume, 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Philippines (Value and Volume, 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Rest of Asia-Pacific (Value and Volume, 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Asia-Pacific Hemodynamic Monitoring Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 84 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 84 pages
- Published: 07-06-2019
Market Overview
The key factors propelling the Asia-Pacific hemodynamic monitoring market are an increase in the number of critically ill geriatric population and rising prevalence of cardiac disorders and diabetes. According to the economic and social commissions for Asia and Pacific, the percentage of people aged 65 years or older is projected to increase from an estimated 16.8% of people out of the total population in 2016, to nearly 23.3% of the population by 2050, in the Asia-Pacific region. Age is associated with a progressive decline of the functional reserve of multiple organ systems. It is, therefore, not surprising that elderly patients may utilize a disproportionate share of healthcare resources, as approximately 92% of older adults have at least one chronic disease, and 77% have at least two. Early and effective hemodynamic management with fluid therapy and administration of vasoactive drugs to maintain vital organ perfusion and oxygen delivery is mandatory in critically ill patients. This is expected to increase the demand for hemodynamic monitoring, which, in turn, may drive the Asia-Pacific hemodynamic monitoring market.
The market is also propelling due to the increase in the number of reported cases of lifestyle-related diseases, like diabetes, obesity, COPD, and cardiac myopathy, among many others, which require medical monitoring by healthcare professionals, in the Asia-Pacific region. Therefore, the rise in the prevalence of cardiac disorders and diabetes is directly proportional to the growth of the hemodynamic monitoring market.
Scope of the Report
As per the scope of this report, hemodynamic monitoring devices are used to measure the blood pressure inside the veins, heart, and arteries. These devices are also used to monitor the blood flow and the concentration of oxygen in the blood.
Key Market Trends
Non-invasive Monitoring Systems is the Segment under Type of System that is Expected to Grow Fastest During the Forecast Period
Invasive monitoring systems dominated the Asia-Pacific hemodynamic monitoring market, as they provide critical care, allow detailed determinations of cardiorespiratory variables, and are used for the effective preoperative assessment of high-risk patients.
The non-invasive hemodynamic monitoring systems segment is expected to register a CAGR of 10%. In the coming years, the non-invasive hemodynamic monitoring system market is expected to witness the highest growth, with China, Japan, and India positioned as growth engines. According to the American Diabetic Association, around 60% of the world’s diabetic population lives in Asia. The prevalence of diabetes in India and China is 8.6% and 9.6%, respectively. India is known as the diabetes capital of the world with more than 60 million diabetics in the country, as of 2014. There is a high growth in the aging population and high prevalence of diabetes and cardiac diseases, which have helped drive the non-invasive hemodynamic monitoring system market.
Competitive Landscape
The Asia-Pacific hemodynamic monitoring market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence by introducing new products with fewer prices.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increase in the Critically Ill Geriatric Population
4.2.2 Rise in the Prevalence of Cardiac Disorders and Diabetes
4.3 Market Restraints
4.3.1 Increased Incidences of Complications Associated with Invasive Monitoring Systems
4.3.2 Precision of Co-determinations Adversely Affected Under Low Flow Conditions
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 System Type
5.1.1 Minimally Invasive Monitoring Systems
5.1.2 Invasive Monitoring Systems
5.1.3 Non-invasive Monitoring Systems
5.2 Application
5.2.1 Laboratory-based Monitoring Systems
5.2.2 Home-based Monitoring Systems
5.2.3 Hospital-based Monitoring Systems
5.3 Product Type
5.3.1 Cardiac Output Monitors
5.3.2 Catheters
5.3.3 Connecting Tubes
5.3.4 Guidewires
5.3.5 IV Fluids
5.3.6 Transducers
5.3.7 Other Product Types
5.4 Geography
5.4.1 Asia-Pacific
5.4.1.1 China
5.4.1.2 Japan
5.4.1.3 India
5.4.1.4 Australia
5.4.1.5 South Korea
5.4.1.6 Rest of Asia-Pacific
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Edwards Life Sciences Corporation
6.1.2 LiDCO Group PLC
6.1.3 ICU Medical Inc.
6.1.4 Schwarzer Cardiotek Gmbh
6.1.5 Koninklijke Philips NV
6.1.6 Cheetah Medical Inc
6.1.7 Getinge AB
6.1.8 GE Healthcare
6.1.9 Dragerwerk AG & Co. KGaA
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
System Type
Minimally Invasive Monitoring Systems
Invasive Monitoring Systems
Non-invasive Monitoring Systems
Application
Laboratory-based Monitoring Systems
Home-based Monitoring Systems
Hospital-based Monitoring Systems
Product Type
Cardiac Output Monitors
Catheters
Connecting Tubes
Guidewires
IV Fluids
Transducers
Other Product Types
Geography
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Asia-Pacific Remote Patient Monitoring Systems Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 86 pages | Published: 17-06-2019 |
- Healthcare
- Mordor Intelligence
- 86 pages
- Published: 17-06-2019
Market Overview
The Asia-Pacific remote monitoring systems market is projected to register a CAGR of almost 12.9%, over the forecast period. Certain factors that are propelling the growth of the market are the rising incidences of chronic diseases due to lifestyle changes, increase in the aging population, need to contain healthcare expenditure, demand for home-based monitoring devices, and ease of use and portability devices to promote the growth.
The adoption of various home-based monitoring devices has helped in the growth of the healthcare industry, drastically. The switch toward home care and preventive care has led to the higher acceptance of remote patient monitoring devices. With the help of these devices, the patients can keep a track of their well-being and the doctors can offer accurate diagnosis. These devices are also helping patients recover better after surgeries and during treatments. However, a paradigm shift toward home-based monitoring is increasing, which is driving the remote patient monitoring systems market.
Scope of the Report
Remote patient monitoring is a technology, which helps in the monitoring of patients outside of a usual hospital or clinical facilities. This helps in increasing the access to care and decreasing the healthcare delivery costs.
Key Market Trends
Heart Monitors are Expected to Witness the Highest CAGR over the Forecast Period
With the advancements in technology and rapid adoption of digital healthcare in developing countries, there is a huge demand for remote monitoring devices. Among these devices or systems, heart monitors have a huge demand across developing countries, such as India and China.
The rising prevalence of heart diseases in the Asia-Pacific region is one of the major factors contributing to the huge demand for heart monitors. According to the World Health Organization, around 26.2% of deaths in the Asia-Pacific region are associated with cardiovascular diseases. Furthermore, the prevalence of hypertension in the region is approximately 16-18%.
Owing to the rising number of people suffering from medical issues, such as hypertension, blood pressure fluctuations, heart failure, etc., the demand for remote monitoring devices is increasing.
Japan Dominates the Market and is Expected to Follow the Same Trend over Forecast Period
Geographically, the Asian market has been segmented under various regions, namely, China, Japan, India, Australia & New Zealand, and South Korea. Currently, Japan dominates the Asia-Pacific patient monitoring system market, which is followed by China, India, and South Korea. The market is majorly driven by factors, like the increasing number of chronic disease in Asia-Pacific, as two in three deaths were caused due to chronic disease.
Competitive Landscape
The Asia-Pacific remote patient monitoring market is moderately competitive and inclusive of the major players, such as GE Healthcare, Abbott Laboratories, Baxter, Boston Scientific, and Omron Healthcare.
Due to the growing digital healthcare market, small players are also focusing on entering the market, and are anticipated to grab a substantial market share in the coming future.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Incidences of Chronic Diseases due to Lifestyle Changes
4.2.2 Increase in Ageing Population
4.2.3 Need to Contain Healthcare Expenditure
4.2.4 Demand for Home-based Monitoring Devices
4.2.5 Ease of Use and Portability Devices to Promote the Growth
4.3 Market Restraints
4.3.1 Resistance from Healthcare Industry Professionals toward the Adoption of Patient Monitoring Systems
4.3.2 Stringent Regulatory Framework
4.3.3 Lack of Trained Staff and Physicians
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Type
5.1.1 Heart Monitors
5.1.2 Breath Monitors
5.1.3 Hematology Monitors
5.1.4 Multi-parameter monitors
5.1.5 Other Types
5.2 By Application
5.2.1 Cancer Treatment
5.2.2 Cardiovascular Disease
5.2.3 Diabetes Treatment
5.2.4 Sleep Disorder
5.2.5 Weight Management and Fitness Monitoring
5.2.6 Other Applications
5.3 By End-users
5.3.1 Home Healthcare
5.3.2 Ambulatory Care Centers
5.3.3 Hospitals
5.3.4 Other End Users
5.4 Geography
5.4.1 Asia-Pacific
5.4.1.1 China
5.4.1.2 Japan
5.4.1.3 India
5.4.1.4 Australia & New Zealand
5.4.1.5 South Korea
5.4.1.6 Rest of Asia-Pacific
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Omron Healthcare
6.1.3 AMD South America Telemedicine
6.1.4 Baxter
6.1.5 Bosch Medical
6.1.6 Boston Scientific
6.1.7 Cardiocom
6.1.8 Covidien
6.1.9 GE Healthcare
6.1.10 Nihon Kohden
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Type
Heart Monitors
Breath Monitors
Hematology Monitors
Multi-parameter monitors
Other Types
By Application
Cancer Treatment
Cardiovascular Disease
Diabetes Treatment
Sleep Disorder
Weight Management and Fitness Monitoring
Other Applications
By End-users
Home Healthcare
Ambulatory Care Centers
Hospitals
Other End Users
Geography
Asia-Pacific
China
Japan
India
Australia & New Zealand
South Korea
Rest of Asia-Pacific
Asia-Pacific Self monitoring Blood Glucose Devices Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 80 pages | Published: 12-06-2019 |
- Healthcare
- Mordor Intelligence
- 80 pages
- Published: 12-06-2019
Market Overview
The Asia-Pacific self-monitoring blood glucose devices market is segmented into blood glucose meters, blood glucose testing strips, and lancets. Self-monitoring blood glucose (SMBG) devices markets across the Asia Pacific are still in their growing phases. In China, the market size for self-monitoring blood glucose devices is projected to reach USD 0.9 billion by 2019. The market is driven by the increasing diabetic population and continuous innovations in the diagnosis and treatment of diabetes. The Chinese and Japanese markets are the most competitive ones, with a significant number of market players and strong local competition.
Asia-Pacific is at the fore front of the diabetic epidemic, with more than 200 million people suffering from diabetes in 2013, and this number is expected to increase in the coming years. 6.3% of the total APAC population was suffering from diabetes in 2015. With the increasing rate of diabetes cases, self-monitoring with glucose meters and strips has become an important aspect of diabetes care and management.
Scope of the Report
This report includes a detailed study about self-monitoring blood glucose devices, test strips and lancets in the Asia-Pacific market, and further study includes hospital usage and home usage of glucometer devices, test strips, and lancets, in each country.
Key Market Trends
In Asia-Pacific, Glucometer Device Segment Registered the Highest CAGR with 10.6%
The personal-use glucometer is expected to see high sales in the future, owing to the rising awareness and reducing costs associated with the glucometer.
Glucometers, which can be used for critically ill patients, have been approved, like the finger stick glucometer that is available in the market.
The glucometer segment is expected to continue to expand in the future, due to the innovative developments in the same, such as glucometers that can be plugged into smartphones using headphone jack, to automatically record the values. Additionally, making the devices light with long efficient batteries would further promote the adoption of glucometer.
China has the Highest Market Share in Asia-Pacific and Will Continue to Grow in the Future with the CAGR of 7.63%
China faces the largest diabetes epidemic in the world. The number of insulin users increased among the Chinese population, with an increase in Type 1 and Type 2 patients. The trend of self-monitoring blood glucose levels increased more among the Type 1 population. The Chinese blood glucose monitoring market has majorly increased to monitor glycosylated haemoglobin (HbA1c) levels.
In 2015, in the Chinese blood glucose monitoring devices market, the consumables accounted for 88.6%, of which, 75.88% of the market share was held by test strips and the 11.2% was occupied by glucometer devices.
Competitive Landscape
The Asia-Pacific self-monitoring blood glucose devices market is highly fragmented with few major manufacturers gaining presence in major countries of the Asia-Pacific market, while the remaining market comprises other local or region-specific manufacturers.
Mergers and acquisitions that happened between players in the recent past helped the companies to strengthen their market presence; for instance, Ascensia Diabetes Care was established itself in 2016 through the acquisition of Bayer Diabetes Care by PHC Holdings (formerly known as Panasonic Healthcare Holdings).
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Self -monitoring Blood Glucose Devices
5.1.1 By Component (Market Size, Value and Volume)
5.1.1.1 Glucometer Devices
5.1.1.2 Test Strips
5.1.1.3 Lancets
5.1.2 By End User
5.1.2.1 Hospital (Market Size, Value and Volume)
5.1.2.1.1 Glucometer Devices
5.1.2.1.2 Test Strips
5.1.2.1.3 Lancets
5.1.2.2 Personal (Market Size, Value and Volume)
5.1.2.2.1 Glucometer Devices
5.1.2.2.2 Test Strips
5.1.2.2.3 Lancets
5.2 By Geography
5.2.1 Asia-Pacific
5.2.1.1 Japan (Market Size, Value and Volume)
5.2.1.1.1 By Component (Glucometer Device, Test Strips, Lancets)
5.2.1.1.2 By End User (Hospital and Home)
5.2.1.1.3 By Company (Roche, Abbott, Johnson & Johnson, and Others)
5.2.1.2 South Korea (Market Size, Value and Volume)
5.2.1.2.1 By Component (Glucometer Device, Test Strips, Lancets)
5.2.1.2.2 By End User (Hospital and Home)
5.2.1.2.3 By Company (Roche, Abbott, Johnson & Johnson, and Others)
5.2.1.3 China (Market Size, Value and Volume)
5.2.1.3.1 By Component (Glucometer Device, Test Strips, Lancets)
5.2.1.3.2 By End User (Hospital and Home)
5.2.1.3.3 By Company (Roche, Abbott, Johnson & Johnson, and Others)
5.2.1.4 India (Market Size, Value and Volume)
5.2.1.4.1 By Component (Glucometer Device, Test Strips, Lancets)
5.2.1.4.2 By End User (Hospital and Home)
5.2.1.4.3 By Company (Roche, Abbott, Johnson & Johnson, and Others)
5.2.1.5 Australia (Market Size, Value and Volume)
5.2.1.5.1 By Component (Glucometer Device, Test Strips, Lancets)
5.2.1.5.2 By End User (Hospital and Home)
5.2.1.5.3 By Company (Roche, Abbott, Johnson & Johnson, and Others)
5.2.1.6 Vietnam (Market Size, Value and Volume)
5.2.1.6.1 By Component (Glucometer Device, Test Strips, Lancets)
5.2.1.6.2 By End User (Hospital and Home)
5.2.1.6.3 By Company (Roche, Abbott, Johnson & Johnson, and Others)
5.2.1.7 Malaysia (Market Size, Value and Volume)
5.2.1.7.1 By Component (Glucometer Device, Test Strips, Lancets)
5.2.1.7.2 By End User (Hospital and Home)
5.2.1.7.3 By Company (Roche, Abbott, Johnson & Johnson, and Others)
5.2.1.8 Indonesia (Market Size, Value and Volume)
5.2.1.8.1 By Component (Glucometer Device, Test Strips, Lancets)
5.2.1.8.2 By End User (Hospital and Home)
5.2.1.8.3 By Company (Roche, Abbott, Johnson & Johnson, and Others)
5.2.1.9 Philippines (Market Size, Value and Volume)
5.2.1.9.1 By Component (Glucometer Device, Test Strips, Lancets)
5.2.1.9.2 By End User (Hospital and Home)
5.2.1.9.3 By Company (Roche, Abbott, Johnson & Johnson, and Others)
5.2.1.10 Thailand (Market Size, Value and Volume)
5.2.1.10.1 By Component (Glucometer Device, Test Strips, Lancets)
5.2.1.10.2 By End User (Hospital and Home)
5.2.1.10.3 By Company (Roche, Abbott, Johnson & Johnson, and Others)
5.2.1.11 Rest of Asia-Pacific (Market Size, Value and Volume)
5.2.1.11.1 By Component (Glucometer Device, Test Strips, Lancets)
5.2.1.11.2 By End User (Hospital and Home)
5.2.1.11.3 By Company (Roche, Abbott, Johnson & Johnson, and Others)
6 MARKET INDICATORS
6.1 Type 1 Diabetes Population (2012-2024)
6.2 Type 2 Diabetes Population (2012-2024)
7 COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Abbott Diabetes Care
7.1.2 Roche
7.1.3 Johnson & Johnson
7.1.4 Arkray
7.1.5 Ascensia Diabetes Care
7.1.6 Agamatrix Inc.
7.1.7 Bionime Corporation
7.1.8 Acon
7.1.9 Medisana
7.1.10 Trivida
7.1.11 I-Sens
7.1.12 Morpen Laboratories
7.1.13 Rossmax
7.2 COMPANY SHARE ANALYSIS
7.2.1 Roche
7.2.2 Johnson & Johnson
7.2.3 Abbott Diabetes Care
7.2.4 Others
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
Self-monitoring Blood Glucose Devices
By Component (Market Size, Value and Volume)
Glucometer Devices
Test Strips
Lancets
By End User
Hospital (Market Size, Value and Volume)
Glucometer Devices
Test Strips
Lancets
Personal (Market Size, Value and Volume)
Glucometer Devices
Test Strips
Lancets
By Geography
Asia-Pacific
Japan (Market Size, Value and Volume)
By Component (Glucometer Device, Test Strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson, and Others)
South Korea (Market Size, Value and Volume)
By Component (Glucometer Device, Test Strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson, and Others)
China (Market Size, Value and Volume)
By Component (Glucometer Device, Test Strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson, and Others)
India (Market Size, Value and Volume)
By Component (Glucometer Device, Test Strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson, and Others)
Australia (Market Size, Value and Volume)
By Component (Glucometer Device, Test Strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson, and Others)
Vietnam (Market Size, Value and Volume)
By Component (Glucometer Device, Test Strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson, and Others)
Malaysia (Market Size, Value and Volume)
By Component (Glucometer Device, Test Strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson, and Others)
Indonesia (Market Size, Value and Volume)
By Component (Glucometer Device, Test Strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson, and Others)
Philippines (Market Size, Value and Volume)
By Component (Glucometer Device, Test Strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson, and Others)
Thailand (Market Size, Value and Volume)
By Component (Glucometer Device, Test Strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson, and Others)
Rest of Asia-Pacific (Market Size, Value and Volume)
By Component (Glucometer Device, Test Strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson, and Others)
Asia-Pacific Wearable Medical Devices Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 65 pages | Published: 17-06-2019 |
- Healthcare
- Mordor Intelligence
- 65 pages
- Published: 17-06-2019
Market Overview
– The propelling factors for the growth of the Asia-Pacific (APAC) wearable medical devices market include the increasing technological advancements and innovations, increasing per-capita income in developing countries, and ease-of-use and interpretation of medical devices.
– The APAC wearable medical devices market is expected to witness prolific growth, owing to rapid technological advancements and innovations. The introduction of new wearable devices, such as smart lenses, wireless ECG devices, wireless heart-rate monitors, and blood glucose monitors, have created high awareness among tech-savvy consumers. With further improvements in device design, user interface, cybersecurity, and battery capacity, the usage of wearable medical devices is expected to rise over the forecast period.
– In addition, the developing and emerging regions are supplied with low cost, or completely knocked down versions of the international products to improve market penetration. However, some manufacturers continue to use a uniform product and pricing strategy across the world, where prices are moderated relatively by currency fluctuations and local assembling capacity. Thus, the high price of the products is further impacting the growth of the market.
– In the Asia-Pacific region, a large pool of population has lifestyle diseases, such as diabetes and obesity, which has increased the risk of cancer. This has raised the concerns levels in the societies to early diagnose the diseases, which increases the demand for wearable devices. Furthermore, the increase in cases of chronic conditions, such as obesity, heart problems, breathing problems, and many more such diseases, helps to drive the Asia-Pacific market.
Scope of the Report
As per the scope of the report, wearable medical devices are capable of diagnosing or monitoring medical conditions, combined with digital health information, typically worn over the body. The demand for wearable medical devices and remote patient monitoring is continuously increasing in the global market. Wearable devices are easy to use, cordless, and can provide information about various factors, such as heart rate, blood pressure, weight, sleeping habits, and other factors.
Key Market Trends
Sports and Fitness is Estimated to have the Largest Share in the Asia-Pacific Wearable Medical Devices Market
Sports and fitness devices are the most popular and widely known healthcare wearables, which are used to keep track of vital parameters. The athletes use wearable devices, which measure their heart rate, blood pressure, etc. People, nowadays, have become health conscious and started using wearable medical devices to keep a check on their vital parameters, like pulse rate, blood pressure, etc. Thus, the rise in awareness regarding fitness and preventive care increased the demand for wearable medical devices.
Competitive Landscape
The key growth strategies adopted by key players include strategic acquisitions, collaborations, and partnerships that may help them expand their geographical presence and strengthen their business position.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Technological Advancements and Innovations
4.2.2 Increasing Per-capita Income in Developing Countries
4.2.3 Ease-of-use and Interpretation of Medical Devices
4.3 Market Restraints
4.3.1 High Cost of Wearable Devices
4.3.2 Unfavorable Reimbursement Issues
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Wearable Vital Sign Monitor
5.1.1.1 Wearable Heart Rate Monitor
5.1.1.2 Wearable Activity Monitor
5.1.1.3 Wearable Electrocardiograph
5.1.1.4 Wearable Sleep Monitor
5.1.2 Wearable Fetal Monitor and Obstetric Device
5.1.3 Neuro-monitoring Device
5.1.4 Pain Management Wearable Medical Device
5.1.5 Glucose/Insulin Monitoring Wearable Device
5.1.6 Respiratory Therapy Wearable Device
5.2 By Application
5.2.1 Sports and Fitness
5.2.2 Remote Patient Monitoring
5.2.3 Home Healthcare
5.3 By Device Type
5.3.1 Watch
5.3.2 Wristband
5.3.3 Clothing
5.3.4 Ear Wear
5.3.5 Other Device Types
5.4 Geography
5.4.1 Asia-Pacific
5.4.1.1 China
5.4.1.2 Japan
5.4.1.3 India
5.4.1.4 Australia
5.4.1.5 South Korea
5.4.1.6 Rest of Asia-Pacific
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Garmin Ltd
6.1.2 Apple Inc.
6.1.3 Fitbit Inc.
6.1.4 Lifesense
6.1.5 Sotera Wireless
6.1.6 LifeWatch AG (Biotelemetry)
6.1.7 Philips Electronics
6.1.8 Samsung
6.1.9 Vital connect
6.1.10 Abbott Laboratories
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Product Type
Wearable Vital Sign Monitor
Wearable Heart Rate Monitor
Wearable Activity Monitor
Wearable Electrocardiograph
Wearable Sleep Monitor
Wearable Fetal Monitor and Obstetric Device
Neuro-monitoring Device
Pain Management Wearable Medical Device
Glucose/Insulin Monitoring Wearable Device
Respiratory Therapy Wearable Device
By Application
Sports and Fitness
Remote Patient Monitoring
Home Healthcare
By Device Type
Watch
Wristband
Clothing
Ear Wear
Other Device Types
Geography
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific